A specific microRNA profile as predictive biomarker for systemic treatment in patients with metastatic colorectal cancer

被引:9
|
作者
Poel, Dennis [1 ,2 ]
Gootjes, Elske C. [1 ,2 ]
Bakkerus, Lotte [1 ,2 ]
Trypsteen, Wim [3 ,4 ]
Dekker, Henk [1 ]
van der Vliet, Hans J. [1 ]
van Grieken, Nicole C. T. [5 ]
Verhoef, Cornelis [6 ]
Buffart, Tineke E. [1 ,7 ]
Verheul, Henk M. W. [1 ,2 ]
机构
[1] VU Univ Med Ctr Amsterdam, Canc Ctr Amsterdam, Dept Med Oncol, Amsterdam UMC, Amsterdam, Netherlands
[2] Radboud Univ Nijmegen, Dept Med Oncol, Med Ctr, Nijmegen, Netherlands
[3] Univ Ghent, Fac Med & Hlth Sci, HIV Cure Res Ctr, Dept Internal Med & Pediat, Ghent, Belgium
[4] Ghent Univ Hosp, Ghent, Belgium
[5] VU Univ Med Ctr Amsterdam, Canc Ctr Amsterdam, Dept Pathol, Amsterdam UMC, Amsterdam, Netherlands
[6] Erasmus MC Canc Inst, Div Surg Oncol, Dept Surg, Rotterdam, Netherlands
[7] Dept Gastrointestinal Oncol, Amsterdam, Netherlands
来源
CANCER MEDICINE | 2020年 / 9卷 / 20期
关键词
chemotherapy; colorectal cancer; metastases; miRNA; response prediction; serum; FOLFIRI PLUS BEVACIZUMAB; 1ST-LINE TREATMENT; CIRCULATING MICRORNAS; FRESH-FROZEN; OPEN-LABEL; EXPRESSION; FLUOROURACIL; CHEMOTHERAPY; COMBINATION; LEUCOVORIN;
D O I
10.1002/cam4.3371
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Palliative systemic therapy is currently standard of care for patients with extensive metastatic colorectal cancer (mCRC). A biomarker predicting chemotherapy benefit which prevents toxicity from ineffective treatment is urgently needed. Therefore, a previously developed tissue-derived microRNA profile to predict clinical benefit from chemotherapy was evaluated in tissue biopsies and serum from patients with mCRC. Methods Samples were prospectively collected from patients (N = 132) who were treated with capecitabine or 5-FU/LV with oxaliplatin +/- bevacizumab. Response evaluation was performed according to RECIST 1.1 after three or four cycles, respectively. Baseline tissue and serum miRNAs expression levels of miR-17-5p, miR-20a-5p, miR-30a-5p, miR-92a-3p, miR-92b-3p, and miR-98-5p were quantified with RT-qPCR and droplet digital PCR, respectively. Combined predictive performance of selected variables was tested using logistic regression analysis. Results From 132 patients, 81 fresh frozen tissue biopsies from metastases and 93 serum samples were available. Based on expression levels of miRNAs in tissue, progressive disease could be predicted with an AUC of 0.85 (95% CI:0.72-0.91) and response could be predicted with an AUC of 0.70 (95% CI:0.56-0.80). This did not outperform clinical parameters alone (respectivelyP = .14 andP = .27). Expression levels of miR-92a-3p and miR-98-5p in serum significantly improved the predictive value of clinical parameters for response to chemotherapy (AUC 0.74, 95% CI:0.64-0.84,P = .003) in this cohort. Conclusions The additive predictive value to clinical parameters of the tissue-derived six miRNA profile for clinical benefit could not be validated in patients with mCRC treated with first-line systemic therapy. Although miR-92a-3p and miR-98-5p serum levels improved the predictive value of clinical parameters, it remained insufficient for clinical decision-making.
引用
收藏
页码:7558 / 7571
页数:14
相关论文
共 50 条
  • [21] Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients
    De Stefano, Alfonso
    Carlomagno, Chiara
    Pepe, Stefano
    Bianco, Roberto
    De Placido, Sabino
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (05) : 1207 - 1213
  • [22] Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer
    Sawada, Kentaro
    Nakamura, Yoshiaki
    Yamanaka, Takeharu
    Kuboki, Yasutoshi
    Yamaguchi, Daisuke
    Yuki, Satoshi
    Yoshino, Takayuki
    Komatsu, Yoshito
    Sakamoto, Naoya
    Okamoto, Wataru
    Fujii, Satoshi
    CLINICAL COLORECTAL CANCER, 2018, 17 (03) : 198 - 205
  • [23] Systemic Therapy for Metastatic Colorectal Cancer
    Saltz, Leonard
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2013, 11 (5.5): : 649 - 652
  • [24] Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer
    Kim, Seung Tae
    Kim, Tae Won
    Kim, Kyu-Pyo
    Kim, Tae-You
    Han, Sae-Won
    Lee, Ji Yun
    Lim, Sung Hee
    Lee, Min-Young
    Kim, Haesu
    Park, Young Suk
    CANCER RESEARCH AND TREATMENT, 2015, 47 (04): : 790 - 795
  • [25] MicroRNA-143 is a putative predictive factor for the response to fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer
    Simmer, Femke
    Venderbosch, Sabine
    Dijkstra, Jeroen R.
    Vink-Borger, Elisa M.
    Faber, Claudius
    Mekenkamp, Leonie J.
    Koopman, Miriam
    De Haan, Anton F.
    Punt, Cornelis J.
    Nagtegaal, Iris D.
    ONCOTARGET, 2015, 6 (26) : 22996 - 23007
  • [26] Specific Treatment Situations in Metastatic Colorectal Cancer
    Arnold, Dirk
    Schmoll, Hans-Joachim
    Lang, Hauke
    Knoefel, Wolfram Trudo
    Ridwelski, Karsten
    Trarbach, Tanja
    Staib, Ludger
    Kirchner, Thomas
    Geissler, Michael
    Seufferlein, Thomas
    Amthauer, Holger
    Riess, Hanno
    Schlitt, Hans J.
    Piso, Pompiliu
    ONKOLOGIE, 2010, 33 : 8 - 18
  • [27] Safety and efficacy review of aflibercept for the treatment of metastatic colorectal cancer
    Lau, David K.
    Mencel, Justin
    Chau, Ian
    EXPERT OPINION ON DRUG SAFETY, 2022, 21 (05) : 589 - 597
  • [28] Metastatic colorectal cancer in the elderly: An overview of the systemic treatment modalities (Review)
    Stec, Rafal
    Bodnar, Lubomir
    Smoter, Marta
    Maczewski, Michal
    Szczylik, Cezary
    ONCOLOGY LETTERS, 2011, 2 (01) : 3 - 11
  • [29] Current Trends in Systemic Therapies in Elderly Patients With Metastatic Colorectal Cancer
    Griffith, Anna
    Sanoff, Hanna
    CURRENT COLORECTAL CANCER REPORTS, 2019, 15 (04) : 105 - 111
  • [30] The changing face of treatment for metastatic colorectal cancer
    Pfeiffer, Per
    Koehne, Claus-Henning
    Qvortrup, Camilla
    EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (01) : 61 - 70